EYLUXV, a new biosimilar for treating serious eye conditions, gains positive EMA recommendation, promising improved patient access and outcomes.

Data from the TEASE-3 and SAGA clinical studies of investigational oral gildeuretinol will be presented during the American Society of Retina Specialists (ASRS) 43rd Annual Scientific Meeting being ...

Modern Retina provides ophthalmology professionals with the latest advancements, research, and expert insights in retinal ...

Due to the changing regulatory landscape, developing and distinguishing new investigational products from approved treatment options is challenging. That is why advances in treatments, especially in ...

Modern Retina provides ophthalmology professionals with the latest advancements, research, and expert insights in retinal care to improve patient outcomes.

Kiora Pharmaceuticals secures a patent for KIO-104, enhancing treatment options for ocular diseases and extending market exclusivity until 2043.

Ocular Therapeutix to showcase its drug delivery solutions at upcoming ophthalmology conferences.

The Phase 3 ARCHER II trial completes enrollment for vonaprument, targeting vision preservation in dry AMD, with results expected in 2026.

Sanofi's SAR446597 receives FDA fast track designation, offering a promising one-time gene therapy for geographic atrophy and reducing treatment frequency.

OpenAI's ChatGPT-4o enhances ophthalmological image generation, producing realistic retinal photographs while highlighting the need for further research in training datasets.

Newsletter Keep your retina practice on the forefront—subscribe for expert analysis and emerging trends in retinal disease management.